Use this button to switch between dark and light mode.

FDA Evaluation of GMP Compliance during COVID-19 Pandemic

November 29, 2022 (1 min read)

Learn how the coronavirus (COVID-19) pandemic forced the U.S. Food and Drug Administration (FDA) to find innovative solutions to continue its manufacturing facility inspection program, including embracing new evaluation tools to assess compliance with current good manufacturing practice regulations (cGMPs) by FDA-regulated companies.

Read now »


Related Content

  • FDA Warning Letters Tracker
    Monitor drug and medical device-focused warning letters issued by the FDA in response to FDA’s determination that a manufacturer has violated, or potentially violated, applicable requirements of the Food, Drug, and Cosmetics Act (FDCA), FDA regulations, or agency guidance.

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.


Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+